AChE is an important therapeutic target for treating AD [13] because the deterioration of cholinergic neurons in the brain and the loss of cholinergic neurotransmission due to ACh degradation are among the leading causes of cognitive decline in patients with AD [13]. This evidence concerns the gene ACHE and Alzheimer disease.